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Abstract 
We present a 42-year-old man with a BMI of 32, who was referred because of proteinuria and 
decreased renal function. We were impressed by his markedly muscular physique. A renal bi-
opsy was performed, which showed focal segmental glomerular sclerosis (FSGS). Is this patient 
merely an obese person with FSGS or is something else going on here? We performed exten-
sive clinical and laboratory examinations, genetic testing, and anthropometric data monitoring 
over time. We transferred our methodology for routine FSGS mutation screening (Sanger se-
quencing) to the Ion Torrent PGM platform with a new custom-targeted NGS gene panel (Ion 
Ampliseq FSGS panel) and tested the performance of the system in two cohorts of patients 
with FSGS. We discuss FSGS in bodybuilders, including possible mechanisms, and review the 
literature. © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
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The Case 
A 42-year-old Caucasian man was referred because of proteinuria and decreased renal 
function. He had developed hypertension several years earlier and was being treated with hy-
drochlorothiazide and telmisartan. The heart rate was 64/min, while the blood pressure was 
146/90 mm Hg. The personal and family histories were negative. His parents, grandparents, 
and brother had no kidney disease. The patient was 174 cm tall, weighed 97 kg, and had a BMI 
of 32. The heart, lungs, abdomen, and neurological examinations were unremarkable. There 
was no edema. We were impressed by his markedly muscular physique. Laboratory tests re-
vealed a serum creatinine of 6.37 mg/dL (estimated glomerular filtration rate [CKD-EPI] <15 
mL/min) and a serum urea of 185 mg/dL (normal 17–48 mg/dL). Endogenous creatinine 
clearance was 33 mL/min. Intact parathyroid hormone was 580.3 ng/L (normal 15.0–65.0 
ng/L). The sodium 140 mmol/L, potassium 4.0 mmol/L and chloride 107 mmol/L concentra-
tions were unremarkable. He had a pH of 7.30, bicarbonate of 18.2 mmol/L, and pCO2 of 52.2 
mm Hg. There was an albuminuria of 3.01 g albumin/g creatinine. The total proteinuria was 
3.98 g protein/g creatinine. Serum creatine kinase (CK 5,995 U/L, normal <190 U/L; with CK-
MB activity 66.4 U/L, normal <24.0 U/L) and myoglobin (1,554 µg/L, normal 28–72 µg/L) 
were elevated. Serum albumin (36 g/L) and protein (64 g/L) levels were in the low-normal 
range. Serum cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein 
levels were 180, 138, and 42 mg/dL under therapy with simvastatin, respectively. Autoim-
mune screen for antineutrophil cytoplasmic antibodies, extractable nuclear antigens, antinu-
clear antibodies, hepatitis, and human immunodeficiency virus serology were negative. Serum 
C3 and C4 complement-fraction levels were within normal limits. An electrocardiogram was 
normal. Renal ultrasound scanning showed kidneys with hyperechogenic renal parenchyma. 
The renal pyramids were not demarcated but a mildly extended renal pelvis was observed 
(Fig. 1a). The urine analysis exhibited few cells, hyaline casts, and heavy proteinuria. A renal 
biopsy was performed (Fig. 1b), consistent with advanced focal segmental glomerular sclero-
sis (FSGS). Is this patient merely an obese person with FSGS or is something else going on 
here? 
The Diagnosis 
Bodybuilding: consequences of anabolic steroids. 
Discussion 
The patient was a German professional bodybuilder who was not fat despite a BMI of 32 
that classified him as an obese person (obesity class 2). He used progressive resistance exer-
cise to develop his musculature from the age of 18–39 years. As part of his bodybuilding regi-
men, he consumed anabolic steroids, muscle growth-stimulating substances, and high-pro-
tein, low-fat diets. For more than 6 months until admission to our hospital, he resumed pro-
gressive resistance exercise and also regularly used anabolic androgenic steroids, including 
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testosterone enanthate (depot 250 mg × 2/week, i.m.), recombinant growth hormone (soma-
totropin 2× 2 IU/day, i.m.), and boldenone 200 mg × 2/week, i.m. In addition, he administered 
trenbolone enanthate (TrENOL 100) 100 mg × 1/week, i.m. and methandienone (Metabolon) 
10 mg × 3/day, p.o., and consumed a high-protein, low-fat diet: protein 1,326 kcal (42.8%), 
carbohydrate 1,615 kcal (52.1%), fat 160 kcal (5.1%), and vitamins, spread over 6 meals a 
day. Our patient reported intense training sessions within the past weeks.  
The poet and play write, Berthold Brecht, once commented: “great sport begins when it 
has ceased to be healthy.” Convincing athletes to adjust their behavior is difficult. Medical care 
is a function of compromises. After renal biopsy and diagnosis, our patient discontinued ana-
bolic steroid abuse and muscle growth-stimulating substances. He continued resistance exer-
cise training, but with less intensity. Figure 2 documents a decrease in serum CK in response 
to these changes, probably indicating reduced outflow from skeletal muscle to the blood 
stream by reduced exercise-related skeletal muscle damage [1], which can be severe in body-
builders taking anabolic androgenic steroids [2]. Nevertheless, his renal function did not im-
prove (Fig. 2). His high intact parathyroid hormone levels in the blood suggest that this in-
crease was not an acute onset of FSGS, but rather a smoldering FSGS that developed over 
years. Our patient continued taking hydrochlorothiazide, telmisartan, and simvastatin. Home 
and ambulatory blood pressure monitoring showed that blood pressure was adequately con-
trolled. 
We followed anthropometric data over time with the air displacement plethysmography 
(BodPod) estimation. Over a 6-month period, his body mass hardly changed (from 96.6 to 98.4 
kg). His lean mass decreased from 88 to 72%, while his body fat increased from 12 to 28%. A 
combination of postadaptive glomerular changes driven by increased lean body mass [3] and 
potential direct nephrotoxic effects of anabolic steroids was mechanistically implicated and a 
guarded prognosis was reported [4, 5]. Our patient’s renal function failed to improve, despite 
a reduction in lean body mass, discontinuation of anabolic steroid drugs, and muscle growth-
stimulating substances (Fig. 2). Genetic factors could be of causal importance. We transferred 
our methodology for routine FSGS mutation screening (Sanger sequencing) to the Ion Torrent 
PGM platform with a new custom-targeted NGS gene panel (Ion Ampliseq FSGS panel). The 
NGS gene panel was validated in two patient cohorts with FSGS (see online suppl. material; 
for all online suppl. material, see www.karger.com/doi/10.1159/000489087). Using this ap-
proach, we did not detect mutations in our patient in the FSGS genes CD2AP, PLCE1, INF2, 
NPHS2, NPHS1, MYO1E, ACTN4, TRPC6, WT1, LMX1B, and LAMB2. Two common APOL1 G1 and 
G2 variants have been identified in populations of African ancestry as risk alleles for primary 
FSGS [6], which were irrelevant to our patient because of his Caucasian ancestry. We detected 
several common DNA variants occurring at a specific position in the FSGS genes (see online 
suppl. Table 1), which could represent candidates for renal risk variants in the differential 
diagnosis of secondary FSGS. 
To our knowledge, an association between bodybuilding and FSGS is rare and has been 
reported in only three case studies, affecting a total of 12 Caucasian and Hispanic patients in 
the USA and Western Europe [4, 5, 7]. There are no reports concerning FSGS and bodybuilding 
in the Asian or African populations. However, we have no reason to believe that this form of 
secondary FSGS spares the Asian or African populations.  
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One reported patient (index patient; see Table 1) resumed anabolic steroid abuse and 
suffered relapse of proteinuria and renal insufficiency [4]. However, whether this improve-
ment in renal function (24-h creatinine clearance or Cockcroft-Gault estimate) was due to dis-
continuation of anabolic steroids, and/or reduction of weight loss, and/or pseudo normaliza-
tion after discontinuation of dietary creatine supplements and/or reduced exercise-induced 
muscle damage is not entirely clear. Supplemental creatine ethyl ester is known to result in 
raised serum creatinine in the absence of true underlying kidney pathology [8, 9]. We also 
used cystatin C to monitor renal function but failed to detect improvement of renal function 
(Fig. 2). Our patient was evaluated for preemptive kidney transplantation given his advanced 
chronic kidney disease. He declined to undergo arteriovenous fistula surgery. 
Our patient resembled a 38-year-old bodybuilder [5] who presented with malignant hy-
pertension and advanced FSGS requiring renal replacement therapy shortly after presenta-
tion. That patient also gave a history of prior abuse of anabolic steroids since the age 18 years, 
claiming to have stopped for a year or so prior to presentation. The authors suggest that ana-
bolic steroid abuse is a direct cause of FSGS [5]. Our patient had long-standing hypertension, 
which per se is known as a risk factor for the development of secondary FSGS. Although oph-
thalmological examination showed no signs of hypertensive retinopathy in our patient, echo-
cardiography revealed normal systolic left ventricular function (LVEF 60%) and concentric 
left ventricular hypertrophy (relative wall thickness >0.45). Renal biopsy showed histological 
signs of long-standing hypertension, such as thickened vessel walls, hyalinosis, and tubu-
lointerstitial fibrosis (see Table 1). These findings are consistent with long-standing hyper-
tension in our patient. Any advanced kidney disease with substantial loss of nephrons is 
known to cause FSGS, and hypertension is viewed as a stress factor to develop the fully ex-
pressed phenotype of FSGS [10]. On the other hand, hypertension is common in FSGS and end-
stage renal disease, namely the current stage of chronic kidney failure of our patient. Accord-
ing to Herlitz et al. [4], patients with FSGS thought to be due to anabolic steroid use had a 
higher incidence of nephrotic syndrome at presentation and more advanced histological evi-
dence of glomerulosclerosis than other patients with secondary FSGS. This finding is in keep-
ing with the advanced biopsy findings in our patient, and the rapid progression to end-stage 
renal failure requiring dialysis in the bodybuilder described by Harrington et al. [5], who also 
had a long prior history of abuse of anabolic steroids. Anabolic steroids could possibly repre-
sent a cause of drug-induced secondary FSGS, independent of the patient’s muscular physique. 
However, there are no experimental animal data to support this idea. Testosterone supple-
mentation can induce podocyte apoptosis that precedes glomerulosclerosis in female estro-
gen receptor knockout mice [11]. Our patient also ingested boldenone, which per se can cause 
glomerulosclerosis, chronic renal injury, and progressive renal failure in rabbits [12]. How-
ever, histopathological analyses did not reveal signs of FSGS in both of the cited animal studies 
[11, 12]. Our patient was also abusing growth hormone-related substances, such as insulin-
like growth factor, which can promote glomerular extracellular matrix production independ-
ent of hemodynamic stimuli [13, 14]. These compounds have also been discussed to play a 
role in secondary FSGS in nonobese patients with increased muscle mass [3]. However, it is 
unclear how relevant these effects are in human kidneys. 
We conclude that increased BMI due to increased muscle mass and/or body fat in combi-
nation with long-term anabolic steroid use and growth-promoting substances should be in-
cluded as risk factors in the differential diagnosis of secondary FSGS. Bodybuilders are a 
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unique patient population that are fixated on their behavior. Simple counseling is well mean-
ing; however, nephrologists may have to recruit other health care professionals when dealing 
with these patients. We are pursuing this option. 
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Fig. 1. Hyperechogenic renal parenchyma (a) and histology consistent with focal segmental glomerular 
sclerosis (b). Segmental obliteration of capillary loop basement membranes is marked by arrows. Periodic 
acid–Schiff. Scale bar, 50 µm.  
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Fig. 2. Renal function, enzymes, and proteinuria showed little change over time. Arrows and dotted line 
indicate discontinuation of anabolic steroid abuse. 
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Table 1. Pathologic findings in patients with FSGS associated with increased muscle mass 
         
         
 Our  
patient 
Index  
patient  
in [4] 
Eight  
patients  
in [4] 
Patient 1 in 
[3] 
Patient 2 in 
[3] 
Patient 3 in 
[3] 
Index  
patient  
in [5]  
Index  
patient  
in [7]  
         
         
Light microscopy         
Glomeruli 8 22 6–61 15 66 55 n/r 12 
Global sclerotic glomeruli 3 16 0–16 3 15 1 n/r 10 
Segmentally sclerotic glomeruli 2 4 1–15 1 10 0 n/r 0 
Tubular atrophy and interstitial 
fibrosis 
 
moderate 
(>50%) 
 
severe (80%) 
 
none-severe 
(80%) 
 
minimal 
 
mild 
 
none 
 
n/r 
 
diffuse 
Interstitial inflammation minimal mild-moder-
ate 
n/r none minimal none n/r n/r 
Vascular disease moderate mild none-moder-
ate 
none mild minimal n/r pro-
nounced 
                  Electron microscopy         
Foot process effacement yes yes yes yes yes yes n/r n/r 
Immune-type electron-dense  
deposits 
 
no 
 
no 
 
n/r 
 
no 
 
no 
 
no 
 
n/r 
 
n/r 
                  Histopathological diagnosis FSGS FSGS FSGS FSGS FSGS FGGS FSGS FGGS 
                  ESRD at biopsy no no 1/9 with fol-
low-up 
no no no yes yes 
         
         
Immunofluorescence was negative for IgG, IgM, IgA, C3, C1q, and kappa and lambda light chains in all patients. FSGS, focal segmental 
glomerulosclerosis, FGGS, focal global glomerulosclerosis. ESRF, end-stage renal failure. n/r, not reported. 
         
 
 
 
